Teva wins battle with Pfizer over Viagra patent

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Teva wins battle with Pfizer over Viagra patent

viagra2-1-45.jpg

The Supreme Court of Canada on Thursday said that Pfizer’s blockbuster patent on the erectile dysfunction drug Viagra is invalid, reversing a Federal Court ruling that blocked Teva's application to market generic Viagra under the Patented Medicines (Notice of Compliance) Act (PM[NOC])

The decision is interesting in that the Supreme Court took the step of finding the patent invalid, rather than simply allowing the Canadian Minister of Health to grant the notice of compliance, said Sean Jackson of IP Osgoode.

viagra2-1-250.jpg

It has also clarified the Canadian disclosure requirement. “Sufficiency of disclosure lies at the very heart of the patent system, so adequate disclosure in the specification is a precondition for the granting of a patent,” said the judgment. In this respect, the Court found Pfizer’s patent lacking. The panel explained: “Although the patent includes the statement that ‘one of the especially preferred compounds induces penile erection in impotent males’, the patent application does not disclose that the compound that works is sildenafil, that it is found in Claim 7, or that the remaining compounds had not been found to be effective in treating ED.”

Pfizer’s patent was due to expire in 2014. Teva said its generic version of the drug will “result in millions in savings to consumers”.

more from across site and SHARED ros bottom lb

More from across our site

Eszter Szakács discusses 5.30 am wake-ups, legal mind games, and eating Nutella in the middle of the night
Counsel explain how AI can create brand protection headaches, but also be used to fight fakes
An AI copyright update in the UK and IP protection efforts by Temu and WeChat were also among the top talking points this week
Mary Till says she has been helping clients navigate policy questions, including staffing concerns at the office
A seminal decision concerning second medical use patents and questions over confidentiality were among the top talking points this fortnight
Managing IP considers some of the key themes from the 2025 Annual Meeting and offers some tips for London 2026
A comparison of the 2024 and 2025 editions of the Managing IP EMEA Awards reveals the firms and companies that have been dominating Europe’s IP market year after year
Tuesday's coverage includes BD tips for aspiring partners, and a foray into the world of SEPs
Exclusive data reveals law firms are failing to go above and beyond for their corporate clients, with in-house counsel saying advisers should consider more transparent billing processes
Arty Rajendra and Gary Moss discuss why ‘thorough and intense’ preparation, plus the odd glass of wine, led to a record FRAND victory for their client
Gift this article